New Jersey, USA-based Merck & Co (NYSE: MRK) has won European approval for Keytruda (pembrolizumab) in combination with platinum-based chemotherapy and pemetrexed. Pemetrexed is marketed as Alimta by Eli Lilly (NYSE: LLY).
The new approval covers the first-line treatment of certain non-small cell lung cancer (NSCLC) patients.
The therapy has been shown to reduce the risk of death by more than 50% compared to pemetrexed and platinum-based chemotherapy alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze